Page 119 - நாஸ்டாக் உலகளாவிய தேர்ந்தெடுக்கவும் சந்தை News Today : Breaking News, Live Updates & Top Stories | Vimarsana
KnowBe4, Inc (KNBE) Prices 9 5M Share IPO at $16/Sh
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
KnowBe4 Announces Pricing of Initial Public Offering
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
ObsEva Annual General Meeting 2021
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL
Erytech Pharma S.A.April 20, 2021 GMT
ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL
ERYTECH invited by FDA to request a pre-BLA meeting
First step in the marketing approval process with the FDA for eryaspase for the treatment of hypersensitive ALL patients based on the positive results of the NOPHO-sponsored Phase 2 clinical trial
Lyon (France) and Cambridge, MA (U.S.), April 20, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the initiation of the process of seeking marketing approval from the U.S. Food and Drug Administration (US FDA) for its lead product candidate eryaspase in patients with acute ly
Share this article
Share this article
MCLEAN, Va., April 20, 2021 /PRNewswire/ Iridium Communications Inc. (Nasdaq:IRDM) ( Iridium ) today reported financial results for the first quarter of 2021 and reiterated its full-year 2021 outlook. Net loss was $5.2 million, or $0.04 per diluted share, for the first quarter of 2021, as compared to net loss of $31.7 million, or $0.24 per diluted share, for the first quarter of 2020. This decrease in net loss was primarily the result of the absence of debt extinguishment costs, which were incurred in the year ago period with Iridium s refinancing of its senior unsecured notes. Operational EBITDA ( OEBITDA )
(1) for the first quarter was $89.8 million, as compared to $92.1 million for the prior-year period, representing a year-over-year decrease of 2% and an OEBITDA margin